{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=25", "query": { "condition": "Melanoma Neoplasms", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 2205, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T19:23:37.385Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Fallopian Tube Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Ovarian Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Primary Peritoneal Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Melanoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-06-26", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-16T19:23:37.385Z", "location_count": 5, "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more", "locations": [ { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419495" }, { "nct_id": "NCT00045357", "title": "Biological Therapy in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 18, "start_date": "2001-11", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2010-09-21", "last_synced_at": "2026-10-16T19:23:37.385Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045357" }, { "nct_id": "NCT00281957", "title": "Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "tipifarnib", "type": "DRUG" }, { "name": "temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2007-08", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-10-16T19:23:37.385Z", "location_count": 173, "location_summary": "Little Rock, Arkansas • Castro Valley, California • Fremont, California + 113 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00281957" }, { "nct_id": "NCT05022901", "title": "An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Ocular Melanoma", "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Delcath Systems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-06-10", "completion_date": "2024-03-01", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-10-16T19:23:37.385Z", "location_count": 5, "location_summary": "Palo Alto, California • Tampa, Florida • Durham, North Carolina + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05022901" }, { "nct_id": "NCT05520294", "title": "Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [ { "name": "High-performance liquid chromatography-tandem mass spectrometry assays", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "21 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "21 Years to 100 Years" }, "enrollment_count": 90, "start_date": "2022-09-01", "completion_date": "2024-08-31", "has_results": false, "last_update_posted_date": "2024-04-17", "last_synced_at": "2026-10-16T19:23:37.385Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05520294" }, { "nct_id": "NCT02120222", "title": "Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Melanoma" ], "interventions": [ { "name": "selinexor", "type": "DRUG" }, { "name": "Correlative studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kari Kendra", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2014-08-22", "completion_date": "2018-04-08", "has_results": false, "last_update_posted_date": "2023-04-04", "last_synced_at": "2026-10-16T19:23:37.385Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02120222" }, { "nct_id": "NCT05625399", "title": "A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Nivolumab + Relatlimab", "type": "DRUG" }, { "name": "rHuPH20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 579, "start_date": "2023-03-06", "completion_date": "2027-11-18", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-16T19:23:37.385Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05625399" }, { "nct_id": "NCT01378975", "title": "A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2011-07", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-10-16T19:23:37.385Z", "location_count": 11, "location_summary": "Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01378975" }, { "nct_id": "NCT04190628", "title": "Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "BRAF V600 Mutation" ], "interventions": [ { "name": "ABM-1310", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ABM Therapeutics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2020-06-16", "completion_date": "2024-04-05", "has_results": false, "last_update_posted_date": "2024-05-21", "last_synced_at": "2026-10-16T19:23:37.385Z", "location_count": 8, "location_summary": "San Francisco, California • Stanford, California • Miami, Florida + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04190628" }, { "nct_id": "NCT03325101", "title": "Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Cryosurgery", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pheresis", "type": "PROCEDURE" }, { "name": "Therapeutic Autologous Dendritic Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2017-11-15", "completion_date": "2020-06-14", "has_results": true, "last_update_posted_date": "2025-06-12", "last_synced_at": "2026-10-16T19:23:37.385Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03325101" } ] }